Poly Medicure enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
14,818————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7907901,065152126
43.143.1———
342342178170146
14,412————
−449−449−88818.620.8
₹1,421.87————
3,4913,4912,9431,6401,388
9.8%9.8%6.0%10.4%10.5%
0.02×————
7.22×————
31.24×————
43.25×————
Reference items — trailing FY values
1,9971,8751,6701,3761,115
461442453358265
333327370294208
—241241266191
−67.7−67.7−83.9−10.9−48.4
—−71.7−86.6−13.7−50.5
—308325277239
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

POLYMED₹1,461.90

Poly Medicure Ltd.

· Pharma & Health
₹ CrorePeersPFIZERRAINBOWONESOURCEKIMSJUBLPHARMAVIJAYAINDGNGRANULESMcap ₹14,818 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————14,817.7
- Cash, Equiv & ST Investments125.7151.61,065.3790.4790.4
+ Minority Interest———43.143.1
+ Total Debt146.4170.2177.6341.6341.6
Enterprise Value————14,412.0
Net Debt (memo)20.818.6-887.7-448.8-448.8
EV per Share————1,421.87
Total Capital1,388.11,640.32,943.33,490.93,490.9
Total Debt/Total Capital10.5510.386.049.799.79
Total Debt/EV————0.02
EV/Sales————7.22
EV/EBITDA————31.24
EV/EBIT————43.25
Reference Items — Trailing FY Values
Sales1,115.21,375.81,669.81,875.31,997.4
EBITDA265.4358.2452.8442.3461.4
EBIT208.2294.3370.2326.8333.2
Operating Cash Flow190.8266.1241.1240.7—
Free Cash Flow-48.4-10.9-83.9-67.7-67.7
FCFF (free cash flow to the firm)-50.5-13.7-86.6-71.7—
Capital Expenditure239.3277.0325.0308.4—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.